Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
$16.59
+0.0%
$19.40
$2.26
$41.72
$178.46M1.4927,680 shs6,374 shs
Enhabit, Inc. stock logo
EHAB
Enhabit
$13.79
+0.1%
$13.74
$6.47
$14.22
$706.21M1.261.20 million shs164,853 shs
Charming Medical Ltd stock logo
MCTA
Charming Medical
$29.36
$29.36
$4.30
$31.70
$497.36MN/AN/A4.25 million shs
Personalis, Inc. stock logo
PSNL
Personalis
$5.93
-1.1%
$6.93
$3.84
$11.50
$622.21M1.961.59 million shs1.24 million shs
The 7 Hottest IPOs On Wall Street’s 2026 Watchlist Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
-2.53%-2.47%+3.05%-51.24%+614.66%
Enhabit, Inc. stock logo
EHAB
Enhabit
+0.07%+0.29%-1.50%+23.69%+69.35%
Charming Medical Ltd stock logo
MCTA
Charming Medical
0.00%0.00%0.00%0.00%+2,935,999,900.00%
Personalis, Inc. stock logo
PSNL
Personalis
-1.32%+8.51%-2.92%-25.68%+24.40%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
$16.59
+0.0%
$19.40
$2.26
$41.72
$178.46M1.4927,680 shs6,374 shs
Enhabit, Inc. stock logo
EHAB
Enhabit
$13.79
+0.1%
$13.74
$6.47
$14.22
$706.21M1.261.20 million shs164,853 shs
Charming Medical Ltd stock logo
MCTA
Charming Medical
$29.36
$29.36
$4.30
$31.70
$497.36MN/AN/A4.25 million shs
Personalis, Inc. stock logo
PSNL
Personalis
$5.93
-1.1%
$6.93
$3.84
$11.50
$622.21M1.961.59 million shs1.24 million shs
The 7 Hottest IPOs On Wall Street’s 2026 Watchlist Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
-2.53%-2.47%+3.05%-51.24%+614.66%
Enhabit, Inc. stock logo
EHAB
Enhabit
+0.07%+0.29%-1.50%+23.69%+69.35%
Charming Medical Ltd stock logo
MCTA
Charming Medical
0.00%0.00%0.00%0.00%+2,935,999,900.00%
Personalis, Inc. stock logo
PSNL
Personalis
-1.32%+8.51%-2.92%-25.68%+24.40%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
1.00
SellN/AN/A
Enhabit, Inc. stock logo
EHAB
Enhabit
2.11
Hold$13.57-1.55% Downside
Charming Medical Ltd stock logo
MCTA
Charming Medical
1.00
SellN/AN/A
Personalis, Inc. stock logo
PSNL
Personalis
2.57
Moderate Buy$11.5098.93% Upside

Current Analyst Ratings Breakdown

Latest BNR, EHAB, PSNL, and MCTA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/21/2026
Personalis, Inc. stock logo
PSNL
Personalis
Reiterated RatingSell (D-)
4/20/2026
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
Reiterated RatingSell (D-)
4/14/2026
Enhabit, Inc. stock logo
EHAB
Enhabit
Reiterated RatingSell (D-)
3/6/2026
Enhabit, Inc. stock logo
EHAB
Enhabit
Reiterated RatingBuyHold$12.00 ➝ $13.80
3/5/2026
Personalis, Inc. stock logo
PSNL
Personalis
Lower Price TargetEqual Weight$11.00 ➝ $10.00
2/27/2026
Personalis, Inc. stock logo
PSNL
Personalis
Boost Price TargetBuy$10.00 ➝ $12.00
2/24/2026
Enhabit, Inc. stock logo
EHAB
Enhabit
Reiterated RatingHoldNeutral$12.00 ➝ $13.80
2/23/2026
Enhabit, Inc. stock logo
EHAB
Enhabit
DowngradeBuyHold$12.50 ➝ $13.80
2/23/2026
Enhabit, Inc. stock logo
EHAB
Enhabit
Boost Price TargetMarket Perform$9.50 ➝ $13.80
2/23/2026
Enhabit, Inc. stock logo
EHAB
Enhabit
Boost Price TargetMarket Perform$9.50 ➝ $13.80
2/23/2026
Enhabit, Inc. stock logo
EHAB
Enhabit
Set Price Target$13.80
(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
$77.16M2.32N/AN/A$7.11 per share2.34
Enhabit, Inc. stock logo
EHAB
Enhabit
$1.06B0.67$1.96 per share7.02$11.05 per share1.25
Charming Medical Ltd stock logo
MCTA
Charming Medical
N/AN/AN/AN/AN/AN/A
Personalis, Inc. stock logo
PSNL
Personalis
$69.65M8.69N/AN/A$2.94 per share1.97
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
-$7.92M-$0.79N/AN/AN/A-10.27%-9.98%-6.69%6/2/2026 (Estimated)
Enhabit, Inc. stock logo
EHAB
Enhabit
-$4.60M-$0.09N/A23.77N/A-0.43%4.71%2.23%N/A
Charming Medical Ltd stock logo
MCTA
Charming Medical
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Personalis, Inc. stock logo
PSNL
Personalis
-$81.27M-$0.91N/AN/AN/A-116.69%-39.13%-29.31%N/A

Latest BNR, EHAB, PSNL, and MCTA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/2/2026Q1 2026
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
-$2.2884N/AN/AN/A$19.21 millionN/A
5/7/2026Q1 2026
Personalis, Inc. stock logo
PSNL
Personalis
-$0.23-$0.29-$0.06-$0.29$14.49 million$15.47 million
3/13/2026Q4 2025
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
N/A-$0.21N/A-$0.21N/A$18.05 million
3/5/2026Q4 2025
Enhabit, Inc. stock logo
EHAB
Enhabit
$0.14$0.14N/A-$0.76$270.56 million$270.40 million
2/26/2026Q4 2025
Personalis, Inc. stock logo
PSNL
Personalis
-$0.31-$0.26+$0.05-$0.26$17.12 million$17.35 million
2/14/2026Q4 2025
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
N/A-$0.21N/A-$0.21N/A$18.05 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
N/AN/AN/AN/AN/A
Enhabit, Inc. stock logo
EHAB
Enhabit
N/AN/AN/AN/AN/A
Charming Medical Ltd stock logo
MCTA
Charming Medical
N/AN/AN/AN/AN/A
Personalis, Inc. stock logo
PSNL
Personalis
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
N/A
2.99
2.79
Enhabit, Inc. stock logo
EHAB
Enhabit
0.76
1.63
1.63
Charming Medical Ltd stock logo
MCTA
Charming Medical
N/AN/AN/A
Personalis, Inc. stock logo
PSNL
Personalis
N/A
6.76
6.61

Institutional Ownership

CompanyInstitutional Ownership
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
30.03%
Enhabit, Inc. stock logo
EHAB
Enhabit
N/A
Charming Medical Ltd stock logo
MCTA
Charming Medical
N/A
Personalis, Inc. stock logo
PSNL
Personalis
61.91%

Insider Ownership

CompanyInsider Ownership
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
30.30%
Enhabit, Inc. stock logo
EHAB
Enhabit
3.40%
Charming Medical Ltd stock logo
MCTA
Charming Medical
N/A
Personalis, Inc. stock logo
PSNL
Personalis
4.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Burning Rock Biotech Limited Sponsored ADR stock logo
BNR
Burning Rock Biotech
1,39010.76 million7.50 millionNot Optionable
Enhabit, Inc. stock logo
EHAB
Enhabit
10,80051.23 million49.48 millionOptionable
Charming Medical Ltd stock logo
MCTA
Charming Medical
4916.94 millionN/AN/A
Personalis, Inc. stock logo
PSNL
Personalis
400104.68 million100.28 millionOptionable

Recent News About These Companies

Breaking Down Personalis: 5 Analysts Share Their Views
Personalis (PSNL) Q4 2025 Earnings Call Transcript
Personalis, Inc. (PSNL) Q4 2025 Earnings Call Transcript

New MarketBeat Followers Over Time

Media Sentiment Over Time

Burning Rock Biotech stock logo

Burning Rock Biotech NASDAQ:BNR

$16.58 +0.01 (+0.03%)
As of 12:35 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.

Enhabit stock logo

Enhabit NYSE:EHAB

$13.78 +0.02 (+0.11%)
As of 12:36 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Enhabit, Inc. provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services. The company offers hospice services, including pain and symptom management, palliative and dietary counseling, social worker visits, spiritual counseling, and bereavement counseling services to meet the individual physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families. The company was formerly known as Encompass Health Home Health Holdings, Inc. and changed its name to Enhabit, Inc. in March 2022. Enhabit, Inc. was founded in 1998 and is based in Dallas, Texas.

Charming Medical stock logo

Charming Medical NASDAQ:MCTA

$29.36 0.00 (0.00%)
As of 05/7/2026 03:30 PM Eastern

We are a Hong Kong-based provider of Traditional Chinese Medicine (TCM)-inspired therapies and products. We offer a wide range of beauty, wellness, and postpartum services and products rooted and influenced by the principles and practices of TCM, such as the use of herbal ingredients, acupuncture techniques, Tuina massage, and dietary guidance. Operating under the Beauty Lab Group (“Beauty Lab”) brand, our Operating Subsidiaries in Hong Kong offer a wide range of TCM-inspired beauty, wellness, and postpartum therapies and products through our four wellness centers in Hong Kong. Our services are designed to meet diverse health improvement needs, including alleviating premenstrual syndrome, menstrual irregularities, dysmenorrhea, leukorrhea, pelvic inflammatory disease, menopausal care, breast health, and other common women’s health conditions. We believe that our TCM-inspired herbal therapies can help balance the female endocrine system and improve women’s constitution and overall health. Additionally, the Operating Subsidiaries offer TCM-inspired therapies tailored to men. We offer a wide range of beauty, wellness, and postpartum services for women with a focus on utilizing TCM approaches in addressing women’s health issues. Our beauty, wellness, and postpartum services include but are not limited to womb-warming therapy, BTS (Beauty, Tailor-made, Slim) pelvic detox therapy, agarwood moxibustion therapy, TCM-inspired prenatal massage, and Indonesian traditional abdominal binding. In addition, under the “Beauty Lab” brand, we also offer supplements products, including (i) TCM-inspired supplements products, such as Beauty Lab home herbal uterine care patch, probiotic intimate wash, and Yin nourishing pill sets, designed to support uterine health, improve physical weakness, and balance endocrine functions for female customers; and (ii) beauty products, including ginseng soothing anti-allergy moisturizing wash, which provide comprehensive care for skin issues, and scalp health. Moreover, we also offer consultancy services to provide TCM-inspired therapy technical training and dietary therapy training to other well-established and reputable beauty salons, massage centers, and similar institutions. In March 2025, we launched a franchise model for our Beauty Lab brand, granting exclusive rights to independent third parties (the “Franchisees”) to operate branded beauty and wellness outlets. Franchisees are authorized to offer services such as scalp and hair care and women’s wellness services under the Beauty Lab brand. We derive franchise-related revenue mainly from initial franchise fees, royalty and promotional fees, brand management fees, training and administration fees. As of March 31, 2025 and as of the date of this prospectus, we had 1 and 3 franchisees, respectively. We generated revenue of $6,221,751 and $6,015,375, respectively, and achieved a net income of $1,199,085 and $821,743, respectively, for the years ended March 31, 2025 and 2024. We generated revenue primarily through the following: (i) beauty, wellness, and postpartum services; (ii) sales of products; (iii) consultancy services; and (iv) franchise activities. For the fiscal years ended March 31, 2025 and 2024, the revenue from beauty, wellness, and postpartum services amounted to $5,967,277 and $5,813,814, representing 96.0% and 96.6% of total revenue, respectively. The revenue from sales of products was $207,766 and $88,992 for the fiscal years ended March 31, 2025 and 2024, representing 3.2% and 1.5% of total revenue, respectively. The revenue from consultancy services was nil and $112,569 for the fiscal years ended March 31, 2025 and 2024, representing 0% and 1.9% of total revenue, respectively. The revenue from franchise activities was $46,708 and nil for the fiscal years ended March 31, 2025 and 2024, representing 0.8% and 0% of total revenue, respectively. Our principal executive office is located Hong Kong.

Personalis stock logo

Personalis NASDAQ:PSNL

$5.93 -0.06 (-1.07%)
As of 12:36 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.